The American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, scheduled for May 29 to June 2, 2026, will feature the unveiling of a clinical research abstract for BAL0891, an anticancer drug being developed by SillaJen.
BAL0891 is currently undergoing Phase 1 clinical trials in the U.S. and South Korea, targeting patients with solid tumors and acute myeloid leukemia (AML). The Phase 1 trial is structured into four sub-trial groups.
These groups include monotherapy for solid tumor patients (Sub-trial 1), combination therapy with immune checkpoint inhibitors (Sub-trial 2), combination therapy with chemotherapy drugs (Sub-trial 3), and monotherapy for AML patients (Sub-trial 4).
At the recent American Association for Cancer Research (AACR) Annual Meeting 2026, two fundamental studies on BAL0891 were presented.
These studies examined BAL0891’s effectiveness using patient-derived gastric cancer organoid models and evaluated the synergistic effects of BAL0891 and G-CSF in triple-negative breast cancer models. The research provided valuable insights into the drug’s pharmacological mechanisms and potential synergies.
A spokesperson for SillaJen commented that having the BAL0891 research accepted at the prestigious ASCO Annual Meeting marks a significant milestone. It intends to continue sharing the research outcomes through official channels, including academic conferences, as it accumulates more clinical data.
